华润双鹤：全资子公司取得药品注册证书

Group 1 - The core point of the article is that China Resources Double Crane has received drug registration certificates for low-calcium peritoneal dialysis solutions from the National Medical Products Administration [1] - China Resources Double Crane's subsidiary, Shanghai Changzheng Fumin Jinshan Pharmaceutical Co., Ltd., is responsible for the newly approved products [1] - As of the report, China Resources Double Crane has a market capitalization of 19.1 billion yuan [1] Group 2 - For the first half of 2025, the revenue composition of China Resources Double Crane is as follows: non-infusion products account for 75.13%, infusion products account for 25.98%, and inter-segment eliminations account for -1.11% [1]